Xylem price target lowered to $158 from $175 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Xylem (XYL) to $158 from $175 and keeps a Neutral rating on the shares. The company reported relatively in-line Q4 results, including strong orders, as underlying demand trends appear solid heading into the new year, but with that said, guidance for Q1 and FY26 was weaker than anticipated due to project delays, weakness in China, and headwinds related to 80/20 initiatives, the analyst tells investors in a research note.